Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
- PMID:18452692
- PMCID: PMC2718421
- DOI: 10.4065/83.5.584
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
Abstract
Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world. In North America, lung cancer has become more predominant among former than current smokers. Yet in some countries, such as China, which has experienced a dramatic increase in the cigarette smoking rate during the past 2 decades, a peak in lung cancer incidence is still expected. Approximately two-thirds of adult Chinese men are smokers, representing one-third of all smokers worldwide. Non-small cell lung cancer accounts for 85% of all lung cancer cases in the United States. After the initial diagnosis, accurate staging of non-small cell lung cancer using computed tomography or positron emission tomography is crucial for determining appropriate therapy. When feasible, surgical resection remains the single most consistent and successful option for cure. However, close to 70% of patients with lung cancer present with locally advanced or metastatic disease at the time of diagnosis. Chemotherapy is beneficial for patients with metastatic disease, and the administration of concurrent chemotherapy and radiation is indicated for stage III lung cancer. The introduction of angiogenesis, epidermal growth factor receptor inhibitors, and other new anti-cancer agents is changing the present and future of this disease and will certainly increase the number of lung cancer survivors. We identified studies for this review by searching the MEDLINE and PubMed databases for English-language articles published from January 1, 1980, through January 31, 2008. Key terms used for this search included non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma, bronchioalveolar cell carcinoma, large cell carcinoma, lung cancer epidemiology, genetics, survivorship, surgery, radiation therapy, chemotherapy, targeted therapy, bevacizumab, erlotinib, and epidermal growth factor receptor.
Similar articles
- First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.Greenhalgh J, et al.Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.Cochrane Database Syst Rev. 2016.Update in:Cochrane Database Syst Rev. 2021 Mar 18;3:CD010383. doi: 10.1002/14651858.CD010383.pub3.PMID:27223332Updated.Review.
- Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features.Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y.Yano T, et al.Int J Clin Oncol. 2011 Aug;16(4):287-93. doi: 10.1007/s10147-010-0160-8. Epub 2011 May 13.Int J Clin Oncol. 2011.PMID:21562939Review.
- Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.Sohn HS, Kwon JW, Shin S, Kim HS, Kim H.Sohn HS, et al.J Clin Pharm Ther. 2015 Dec;40(6):661-71. doi: 10.1111/jcpt.12332. Epub 2015 Nov 17.J Clin Pharm Ther. 2015.PMID:26573867
- Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK.Komaki R, et al.Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):317-24. doi: 10.1016/j.ijrobp.2015.02.005.Int J Radiat Oncol Biol Phys. 2015.PMID:25968826Free PMC article.Clinical Trial.
- Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.Zheng L, Wang Y, Xu Z, Yang Q, Zhu G, Liao XY, Chen X, Zhu B, Duan Y, Sun J.Zheng L, et al.Oncologist. 2019 Aug;24(8):1031-e612. doi: 10.1634/theoncologist.2019-0285. Epub 2019 Apr 30.Oncologist. 2019.PMID:31040256Free PMC article.Clinical Trial.
Cited by
- hnRNP U enhances caspase-9 splicing and is modulated by AKT-dependent phosphorylation of hnRNP L.Vu NT, Park MA, Shultz JC, Goehe RW, Hoeferlin LA, Shultz MD, Smith SA, Lynch KW, Chalfant CE.Vu NT, et al.J Biol Chem. 2013 Mar 22;288(12):8575-8584. doi: 10.1074/jbc.M112.443333. Epub 2013 Feb 8.J Biol Chem. 2013.PMID:23396972Free PMC article.
- [Expression and clinical significance of the thyroid transcription factor 1 in Xuanwei lung adenocarcinoma].Zu Y, Wang X, Liu X, Chen Y, Li C, Shang X, Xie Y, Zhao H, Wang J.Zu Y, et al.Zhongguo Fei Ai Za Zhi. 2013 Mar;16(3):131-7. doi: 10.3779/j.issn.1009-3419.2013.03.03.Zhongguo Fei Ai Za Zhi. 2013.PMID:23514941Free PMC article.Chinese.
- Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects.Huang T, Peng L, Han Y, Wang D, He X, Wang J, Ou C.Huang T, et al.Front Immunol. 2022 Aug 26;13:922301. doi: 10.3389/fimmu.2022.922301. eCollection 2022.Front Immunol. 2022.PMID:36090974Free PMC article.Review.
- BPR0C261, An Analogous of Microtubule Disrupting Agent D-24851 Enhances the Radiosensitivity of Human Non-Small Cell Lung Cancer Cells via p53-Dependent and p53-Independent Pathways.Leu JD, Lin ST, Chen CT, Chang CA, Lee YJ.Leu JD, et al.Int J Mol Sci. 2022 Nov 15;23(22):14083. doi: 10.3390/ijms232214083.Int J Mol Sci. 2022.PMID:36430560Free PMC article.
- Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer.Huang Y, Wang J, Hu Y, Cao P, Wang G, Cai H, Wang M, Yang X, Wei Z, Ye X.Huang Y, et al.Front Oncol. 2022 Aug 26;12:938827. doi: 10.3389/fonc.2022.938827. eCollection 2022.Front Oncol. 2022.PMID:36091128Free PMC article.
References
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar–Apr;58(2):71–96. Epub 2008 Feb 20. - PubMed
- Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database [abstract 7082] J Clin Oncol. 2006;24(18S) suppl:384S.
- Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83(3):355–367. - PubMed
- Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128(1):452–462. - PubMed
- Zhang H, Cai B. The impact of tobacco on lung health in China. Respirology. 2003;8(1):17–21. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous